Insider Selling: Amarin Co. plc (AMRN) General Counsel Sells $60,033.16 in Stock

Amarin Co. plc (NASDAQ:AMRN) General Counsel Joseph T. Kennedy sold 3,173 shares of the stock in a transaction on Friday, January 11th. The shares were sold at an average price of $18.92, for a total value of $60,033.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ AMRN opened at $18.00 on Monday. Amarin Co. plc has a 52 week low of $2.35 and a 52 week high of $23.33. The firm has a market capitalization of $4.85 billion, a P/E ratio of -72.00 and a beta of 1.11.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $55.00 million during the quarter, compared to the consensus estimate of $60.63 million. The firm’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.04) EPS. On average, analysts expect that Amarin Co. plc will post -0.38 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on AMRN shares. Cantor Fitzgerald increased their price target on Amarin from $15.00 to $35.00 in a research note on Friday, October 5th. Citigroup dropped their price target on Amarin to $20.00 in a research note on Tuesday, January 8th. Jefferies Financial Group increased their price target on Amarin from $7.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective (up previously from $10.00) on shares of Amarin in a research report on Tuesday, September 25th. Finally, BidaskClub upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Friday, October 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $33.20.

A number of large investors have recently added to or reduced their stakes in AMRN. Signature Estate & Investment Advisors LLC acquired a new stake in Amarin in the third quarter valued at about $137,000. BKS Advisors LLC acquired a new stake in Amarin in the third quarter valued at about $162,000. First Republic Investment Management Inc. acquired a new stake in Amarin in the third quarter valued at about $163,000. Ogorek Anthony Joseph NY ADV acquired a new stake in Amarin in the fourth quarter valued at about $166,000. Finally, Laurel Wealth Advisors Inc. acquired a new stake in Amarin in the third quarter valued at about $170,000. 42.94% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Insider Selling: Amarin Co. plc (AMRN) General Counsel Sells $60,033.16 in Stock” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2019/01/14/insider-selling-amarin-co-plc-amrn-general-counsel-sells-60033-16-in-stock.html.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Story: When is a capital gain realized?

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit